Finally, the first and the largest #metaanalysis on the #upfront combination #lipid lowering therapy (#LLT) of moderate to high intensity #statin#therapy and #ezetimibe vs statin monotherapy has been released in the @MayoProceedings‼️
Based on the data from 14 studies with 108,373 very high-risk #patients we showed that #combination LLT:
👉significantly more effectively reduced #LDLC level from baseline (by mean −12.96 mg/dL);
👉 significantly reduced all-cause #mortality (by 19%; with the longer the better results), major adverse cardiovascular events (#MACE; by 18%) and #stroke incidence (by 17%) when compared with statin monotherapy;
👉the network meta-analysis (#NMA) confirmed these results with more pronounced values: significant additional LDL-C reduction by −15.16 mg/dL, 49% reduction of all-cause mortality and 39% reduction of MACE in comparison to high intensity statin therapy;
👉NMA also revealed that moderate-intensity statins combined with ezetimibe had a significantly lower #discontinuation rate compared with high-intensity statins (by 44%).
‼️Forthcoming #guidelines should consider the #upfront lipid-lowering combination therapy for more effective LDL-C goal achievement and significant reduction of #cardiovascular disease outcomes and mortality in high- and very high-risk patients.
For the full paper please see:
https://t.co/3r9kdoISzu...
These results have been also press-released and have been already published in the:
▶️@BBC Science Focus Magazine: https://t.co/WyXN6xqiLT...
▶️@medical_xpress: https://t.co/8QZGFyFAqP...
▶️@EurekAlert: https://t.co/p4h6sj9QnS